Apreo Health® Adds Independent Director and Strategic Investor 

MENLO PARK, Calif., May 13, 2026 /PRNewswire/ — Apreo Health, a clinical-stage medical device company pioneering a tissue-sparing treatment for severe emphysema, today announced the appointment of David Amerson to its Board of Directors and a strategic investment from OSF Ventures, the corporate investment arm of OSF HealthCare. The company also announced it will present new clinical data at the American […]

Apreo Health® Announces Presentation & Publication of FIH Clinical Data

MENLO PARK, Calif.–(BUSINESS WIRE)–Apreo Health, a clinical-stage medical device company developing a novel, tissue-sparing treatment for severe emphysema, today announced the presentation of first-in-human six-month clinical data from the BREATHE 1&2 trials in a late-breaking abstract session at the American Thoracic Society (ATS) 2025 International Conference in San Francisco. The study was simultaneously published in […]

Apreo Health to Present First-in-Human Data for Novel Airway Scaffold at ATS 2025

MENLO PARK, Calif.–(BUSINESS WIRE)–Apreo Health, a clinical-stage medical device company developing a novel, tissue-sparing treatment for severe emphysema, today announced its emergence from stealth and upcoming presentation of first-in-human clinical data at the American Thoracic Society (ATS) 2025 International Conference, May 16-21 in San Francisco. The company’s BREATHE 1&2 feasibility studies will be presented as […]